Engineering Mesenchymal Stem Cells with Antioxidant Catalase‐Loaded Metal–Organic Frameworks for Targeted Spinal Cord Injury Therapy
Source abstract
Abstract
Abstract Spinal cord injury (SCI) therapy is challenging because of the associated irreversible neurological deficits. These deficits are caused by primary damage and secondary pathological processes such as oxidative stress and inflammation. Although mesenchymal stem cells (MSC) demonstrate potential in SCI treatment by promoting tissue repair and neuroprotection, the high reactive oxygen species (ROS) levels in the SCI microenvironment compromise their therapeutic efficacy. In this study, an MSC‐based cell–drug conjugate (CDC) system is developed by conjugating catalase (CAT)‐loaded metal–organic frameworks (MOF) to MSC, generating a C@M‐MSC platform. The C@M‐MSC system maintains MSC viability, preserves stemness, and mitigates ROS‐induced cellular damage. Furthermore, C@M‐MSC substantially modulates the inflammatory microenvironment by reducing inflammatory cytokine production and shifting microglial polarization toward the anti‐inflammatory M2 phenotype. In vivo studies confirm the targeted accumulation of C@M‐MSC in SCI lesions. This accumulation improves motor functioning, bladder control, and neuronal recovery. Thus, the C@M‐MSC system is a versatile therapeutic strategy that mitigates oxidative stress and enhances tissue repair, offering potential applications beyond SCI. It offers a foundation for broader clinical applications in regenerative medicine and can be integrated with other therapeutic strategies.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Spinal Cord Injury Research · Graphene and Nanomaterials Applications · Conducting polymers and applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Nanomedicine Research Center The Third Affiliated Hospital Sun Yat‐sen University Guangzhou 510630 P. R. China
PCFM Lab of Ministry of Education School of Materials Science and Engineering Sun Yat‐sen University Guangzhou 510275 P. R. China
Department of Gynecology The Sixth Affiliated Hospital Sun Yat‐sen University Guangzhou 510655 P. R. China
Funding
National Key Research and Development Program of China
References (50)
Show source-provided references
1. 10.1016/S0140-6736(02)07603-110.1016/S0140-6736(02)07603-1 ↗
2. 10.3390/ijms2120753310.3390/ijms21207533 ↗
3. 10.1007/s11910-019-0984-110.1007/s11910-019-0984-1 ↗
4. 10.1016/j.biopha.2017.04.12610.1016/j.biopha.2017.04.126 ↗
5. 10.1038/sc.2011.11110.1038/sc.2011.111 ↗
6. 10.1016/j.neurobiolaging.2016.07.02910.1016/j.neurobiolaging.2016.07.029 ↗
7. 10.1002/adhm.20230012310.1002/adhm.202300123 ↗
8. 10.1021/acsnano.3c1240210.1021/acsnano.3c12402 ↗
9. 10.1038/s41467-024-46259-y10.1038/s41467-024-46259-y ↗
10. 10.1016/j.redox.2023.10287110.1016/j.redox.2023.102871 ↗
11. 10.1186/scrt51610.1186/scrt516 ↗
12. 10.1186/s11658-022-00359-z10.1186/s11658-022-00359-z ↗
13. 10.4252/wjsc.v6.i2.12010.4252/wjsc.v6.i2.120 ↗
14. 10.1016/j.jconrel.2023.03.05710.1016/j.jconrel.2023.03.057 ↗
15. 10.1002/jcp.2966010.1002/jcp.29660 ↗
16. 10.1177/096368971773540710.1177/0963689717735407 ↗
17. 10.3390/biology1004026710.3390/biology10040267 ↗
18. 10.1016/j.ajme.2017.09.00110.1016/j.ajme.2017.09.001 ↗
19. Krishnamurthy P. · Antioxidant Enzyme · 2012 · 1 · 3
20. 10.1016/j.addr.2014.10.00510.1016/j.addr.2014.10.005 ↗
21. 10.1016/j.ymgme.2015.11.00110.1016/j.ymgme.2015.11.001 ↗
22. 10.1016/j.ccr.2022.21441410.1016/j.ccr.2022.214414 ↗
23. 10.1021/acsnano.4c0870810.1021/acsnano.4c08708 ↗
24. 10.1016/j.jconrel.2024.06.03510.1016/j.jconrel.2024.06.035 ↗
25. Kim G. U. · Adv. Mater. · 2021 · 22
26. 10.1002/med.2186510.1002/med.21865 ↗
27. 10.1007/s12192-014-0560-110.1007/s12192-014-0560-1 ↗
28. 10.1007/s12015-023-10658-310.1007/s12015-023-10658-3 ↗
29. Guo C. · Neural Regener. Res. · 2003 · 8 · 2013
30. 10.3390/ijms2218970610.3390/ijms22189706 ↗
31. 10.1111/jcmm.1303410.1111/jcmm.13034 ↗
32. 10.5966/sctm.2015-021710.5966/sctm.2015-0217 ↗
33. Liu F. · J. Cell. Mol. Med. · 2019 · 10 · 1
34. 10.1177/002203451770607010.1177/0022034517706070 ↗
35. 10.1002/j.2040-4603.2015.tb00596.x10.1002/j.2040-4603.2015.tb00596.x ↗
36. 10.3389/fncel.2019.0052510.3389/fncel.2019.00525 ↗
37. 10.1038/s41582-019-0280-310.1038/s41582-019-0280-3 ↗
38. 10.1002/dneu.2278010.1002/dneu.22780 ↗
39. 10.1038/s41392-024-01852-x10.1038/s41392-024-01852-x ↗
40. 10.1186/s13287-016-0394-010.1186/s13287-016-0394-0 ↗
41. 10.3390/ijms1810208710.3390/ijms18102087 ↗
42. 10.1016/j.ymeth.2015.03.00210.1016/j.ymeth.2015.03.002 ↗
43. 10.1016/j.jconrel.2018.12.01910.1016/j.jconrel.2018.12.019 ↗
44. 10.1038/s41551-024-01230-610.1038/s41551-024-01230-6 ↗
45. 10.1038/s41578-020-00269-610.1038/s41578-020-00269-6 ↗
46. 10.1038/s41419-020-02993-x10.1038/s41419-020-02993-x ↗
47. 10.1016/j.expneurol.2014.04.02610.1016/j.expneurol.2014.04.026 ↗
48. 10.1097/01.brs.0000162402.79482.fd10.1097/01.brs.0000162402.79482.fd ↗
49. 10.1016/j.jconrel.2019.12.00110.1016/j.jconrel.2019.12.001 ↗
50. 10.1002/advs.20220599710.1002/advs.202205997 ↗